|
Medical News FDA Application Is Submitted for Evaluating HIV TreatmentJanuary 13, 2004 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! Gilead Sciences Inc. has submitted an investigational new-drug application to the Food and Drug Administration to evaluate GS 9005, a potential protease inhibitor therapy that could be taken once daily. The drug's creator said GS 9005 might have a resistance profile that is distinct from commercially available drugs in the protease inhibitor class. Gilead plans to test the drug in healthy volunteers as well as HIV-positive patients. As an experimental drug, GS 9005 has not been determined to be safe or effective in humans for its intended use, Gilead said. Wall Street Journal 01.13.04 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
|
|